Cris Loiren Rodriguez

Array ( [id] => 16506197 [patent_doc_number] => 20200385453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 16/892533 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16892533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096925 [patent_doc_number] => 20210284716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => ACE2-Fc Trap [patent_app_type] => utility [patent_app_number] => 16/880804 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238311 [patent_doc_number] => 20200255545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => TARGETED MODIFIED IL-1 FAMILY MEMBERS [patent_app_type] => utility [patent_app_number] => 16/860660 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466783 [patent_doc_number] => 20200368320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => COMPOSITIONS INCLUDING IL-18 AND IL-22 AND THEIR USE IN ANTI-VIRAL THERAPIES [patent_app_type] => utility [patent_app_number] => 16/856496 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190839 [patent_doc_number] => 20200231688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => ANTIBODY MOLECULES [patent_app_type] => utility [patent_app_number] => 16/838415 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282703 [patent_doc_number] => 20200276305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/824613 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16824613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398836 [patent_doc_number] => 20200339694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => ACTIVATABLE ANTIBODIES THAT BIND INTERLEUKIN-6 RECEPTOR AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/796652 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452602 [patent_doc_number] => 20200362028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => ANTIBODIES AGAINST IL-1 BETA [patent_app_type] => utility [patent_app_number] => 16/783339 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483984 [patent_doc_number] => 20200377585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/784173 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960635 [patent_doc_number] => 20200164069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => BINDING MOLECULES SPECIFIC FOR IL-21 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/782541 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525267 [patent_doc_number] => 20200399347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => IL-22BP COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASE THEREWITH [patent_app_type] => utility [patent_app_number] => 16/780588 [patent_app_country] => US [patent_app_date] => 2020-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16780588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204832 [patent_doc_number] => 20200237822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => COMPOSITIONS AND METHODS FOR STIMULATING NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 16/752040 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16752040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866267 [patent_doc_number] => 20200140537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Treatment of Genital Psoriasis [patent_app_type] => utility [patent_app_number] => 16/740747 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483983 [patent_doc_number] => 20200377584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/736487 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18084383 [patent_doc_number] => 11534490 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Methods of treating psoriasis using IL-17 antagonists [patent_app_type] => utility [patent_app_number] => 16/720351 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 29912 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16720351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770875 [patent_doc_number] => 10981964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Fusion protein comprising IL-4 and IL-10 [patent_app_type] => utility [patent_app_number] => 16/707435 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17171 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506196 [patent_doc_number] => 20200385452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/700823 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898429 [patent_doc_number] => 20200148733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => NOVEL INTERLEUKIN-17A-SPECIFIC AND INTERLEUKIN-23-SPECIFIC BINDING POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/691012 [patent_app_country] => US [patent_app_date] => 2019-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46158 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16691012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931739 [patent_doc_number] => 12304936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Interleukin 21 protein (IL21) mutant and encoding nucleic acid [patent_app_type] => utility [patent_app_number] => 17/296036 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 3218 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931149 [patent_doc_number] => 20200157208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => COMBINATION OF AN ANTIBODY THAT BINDS TO THE P19 SUBUNIT OF HUMAN IL-23 AND A HYALURONIDASE ENZYME [patent_app_type] => utility [patent_app_number] => 16/686921 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16686921 [rel_patent_id] =>[rel_patent_doc_number] =>)